The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia

Jill Samis; Paul Lee; Donald Zimmerman; Meinolf Suttorp; Nobuko Hijiya

doi:10.1002/pbc.26703

The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia

Jill Samis^*, Paul Lee, Donald Zimmerman, Meinolf Suttorp, Nobuko Hijiya

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Article number	e26703
Journal	Pediatric Blood and Cancer
Volume	64
Issue number	12
DOIs	https://doi.org/10.1002/pbc.26703
State	Published - Dec 2017

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.26703

Cite this

@article{ff144b3eefd44657a719ec6d654992c7,

title = "The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia",

author = "Jill Samis and Paul Lee and Donald Zimmerman and Meinolf Suttorp and Nobuko Hijiya",

note = "Funding Information: Dr. Hjijya has served as a consultant for Novartis. Dr. Suttorp has received research funding from Novartis and Bristol-Myers Squibb and served as an expert witness for Pfizer. Drs. Samis, Lee, and Zimmerman have nothing to disclose.",

year = "2017",

month = dec,

doi = "10.1002/pbc.26703",

language = "English (US)",

volume = "64",

journal = "Medical and Pediatric Oncology",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "12",

}

TY - JOUR

T1 - The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia

AU - Samis, Jill

AU - Lee, Paul

AU - Zimmerman, Donald

AU - Suttorp, Meinolf

AU - Hijiya, Nobuko

N1 - Funding Information: Dr. Hjijya has served as a consultant for Novartis. Dr. Suttorp has received research funding from Novartis and Bristol-Myers Squibb and served as an expert witness for Pfizer. Drs. Samis, Lee, and Zimmerman have nothing to disclose.

PY - 2017/12

Y1 - 2017/12

UR - http://www.scopus.com/inward/record.url?scp=85023167291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023167291&partnerID=8YFLogxK

U2 - 10.1002/pbc.26703

DO - 10.1002/pbc.26703

M3 - Letter

C2 - 28696050

AN - SCOPUS:85023167291

SN - 1545-5009

VL - 64

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

IS - 12

M1 - e26703

ER -

The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this